false00011368690001136869zbh:M2425NotesDue2026Member2026-05-222026-05-2200011368692026-05-222026-05-220001136869us-gaap:CommonStockMember2026-05-222026-05-220001136869zbh:M3518NotesDue2032Member2026-05-222026-05-220001136869zbh:M1164NotesDue2027Member2026-05-222026-05-22

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 22, 2026

 

 

ZIMMER BIOMET HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-16407

13-4151777

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

345 East Main Street

 

Warsaw, Indiana

 

46580

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (574) 373-3333

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.01 par value

 

ZBH

 

New York Stock Exchange

2.425% Notes due 2026

 

ZBH 26

 

New York Stock Exchange

1.164% Notes due 2027

 

ZBH 27

 

New York Stock Exchange

3.518% Notes due 2032

 

ZBH 32

 

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

Zimmer Biomet Holdings, Inc. (the “Company”) held its annual meeting of shareholders on May 22, 2026. Shareholders took the following actions:

elected ten (10) directors for one-year terms ending at the 2027 annual meeting of shareholders (Proposal 1);
ratified the Audit Committee’s appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2026 (Proposal 2);
approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s proxy statement (Proposal 3); and
rejected a shareholder proposal on Independent Board Chairman (Proposal 4).

 

The vote tabulation for each proposal follows:

 

Proposal 1 – Election of Directors

 

Nominee

For

Against

Abstain

Broker Non-Votes

Betsy J. Bernard

162,573,610

6,060,594

92,412

12,009,707

Michael J. Farrell

164,446,421

4,180,484

99,711

12,009,707

Robert A. Hagemann

162,498,257

6,126,364

101,995

12,009,707

Arthur J. Higgins

164,389,482

4,236,047

101,087

12,009,707

Maria Teresa Hilado

163,739,579

4,797,047

189,990

12,009,707

Syed Jafry

165,972,307

2,648,596

105,713

12,009,707

Sreelakshmi Kolli

166,889,697

1,734,443

102,476

12,009,707

Devdatt Kurdikar

160,889,975

7,634,226

202,415

12,009,707

Louis A. Shapiro

167,514,405

1,110,244

101,967

12,009,707

Ivan Tornos

162,652,958

5,540,638

533,020

12,009,707

Proposal 2 – Ratification of the Appointment of the Independent Registered Public Accounting Firm

 

For

Against

Abstain

Broker Non-Votes

172,738,361

7,887,786

110,176

0

Proposal 3 – Advisory Vote to Approve Named Executive Officer Compensation

 

For

Against

Abstain

Broker Non-Votes

160,066,066

8,386,847

273,703

12,009,707

Proposal 4 – Approval of Shareholder Proposal on Independent Board Chair

 

For

Against

Abstain

Broker Non-Votes

31,288,886

137,043,058

394,672

12,009,707

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d)
Exhibits

 

EXHIBIT INDEX

Exhibit No.

 

Description

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 27, 2026

 

 

ZIMMER BIOMET HOLDINGS, INC.

 

 

 

 

By:

/s/ Chad F. Phipps

 

Name:

Chad F. Phipps

 

Title:

Senior Vice President, Chief Legal and Corporate Affairs Officer and Secretary